Dalery J, Bouhassira M, Kress J P, Lancrenon S, Tafani A, Hantouche E G
Hôpital Le Vinatier, Lyon Bron.
Encephale. 1995 May-Jun;21(3):217-25.
A multi-centre study was designed to evaluate the efficacy and tolerance of fluoxetine in two groups of major depression: "agitated-anxious" and "blunted-retarded". The study included 50 patients presenting a major depressive episode (following DSM III-R criteria and score > or = 20 on MADRS): 26 in "agitated-anxious" group (score > or = 15 on Hamilton anxiety scale and > or = 10 on Tyrer anxiety brief scale) and 24 in the "blunted-retarded" group (score > or = 15 on Widlöcher retardation scale and > or = 10 on Abrams-Taylor blunted affect scale). After one week period on placebo, all patients were treated in an open design with fluoxetine at a fixed daily dose of 20 mg and followed on a period of 6 weeks with active treatment. In spite of a significant antidepressant efficacy of fluoxetine in the two groups, better results were observed in the "agitated-anxious" depressed group: marked improvement on MADRS total score at day 42 (76% decrease vs 62% in the "blunted-retarded" group, p = 0.012), greater number of "responders" defined by a decrease > or = 50% on MADRS total score and a total score < or = 12 (95% vs 63%, p = 0.04), better patient's global impression on efficacy (54% of "excellent efficacy" vs 18%, p = 0.012), more improvement on HSCL-58 total score (mean decrease of 69% vs 39%, p = 0.016), higher improvement on "hostility/interpersonal hypersensitivity" score (mean decrease of 74% vs 37%, p = 0.001) and on "anger attacks/irritability" sub-score (mean decrease of 73% vs 30%, p = 0.0002).(ABSTRACT TRUNCATED AT 250 WORDS)
一项多中心研究旨在评估氟西汀在两组重度抑郁症患者中的疗效和耐受性,这两组分别为“激越 - 焦虑型”和“迟滞 - 钝挫型”。该研究纳入了50例符合重度抑郁发作的患者(遵循DSM III - R标准且MADRS评分≥20):“激越 - 焦虑型”组26例(汉密尔顿焦虑量表评分≥15且泰勒简易焦虑量表评分≥10),“迟滞 - 钝挫型”组24例(维德洛赫尔迟缓量表评分≥15且艾布拉姆斯 - 泰勒情感迟钝量表评分≥10)。在接受一周安慰剂治疗后,所有患者采用开放设计,给予固定日剂量20mg的氟西汀治疗,并在积极治疗阶段持续观察6周。尽管氟西汀在两组中均具有显著的抗抑郁疗效,但在“激越 - 焦虑型”抑郁组中观察到了更好的结果:在第42天MADRS总分有显著改善(下降76%,而“迟滞 - 钝挫型”组为62%,p = 0.012);更多“有效者”,定义为MADRS总分下降≥50%且总分≤12(95%对63%,p = 0.04);患者对疗效的总体印象更好(“疗效极佳”的比例为54%对18%,p = 0.012);HSCL - 58总分改善更多(平均下降69%对39%,p = 0.016);“敌意/人际过敏”评分改善更高(平均下降74%对37%,p = 0.001)以及“愤怒发作/易怒”子评分改善更高(平均下降73%对30%,p = 0.0002)。(摘要截断于250字)